Treating solid tumors remains a major challenge due to their heterogeneity and limited blood supply, which restrict the effectiveness of traditional anticancer therapies. However, macrophage-based drug delivery offers a promising new approach.
A recent BioWorld article explores how macrophage-drug conjugates (MDCs) can overcome these challenges by actively infiltrating hypoxic tumor regions and delivering therapeutic agents directly to cancer cells. This approach has shown preclinical success, opening new possibilities for solid tumor treatment.
For a deeper dive into this exciting field, read the full article here:
🔗 Macrophage-drug conjugate platform shows preclinical benefits for solid tumor therapy
